Adult With Solid CancerCIRCAN MAPNCT05089747
CIRculating CANcer MAster-Protocol
An observational study of Adult With Solid Cancer, run by Hospices Civils de Lyon at 7 sites in France.
Trial summary
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adult With Solid Cancer
- What is being tested?
- Blood sampling for biomarker analysis (microRNA, circulating DNA…)
- How many people
- 6,000 participants
- Where
- 7 sitesFrance
- Study dates
- 5 Dec 2022to 1 Dec 2047
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult with solid cancer
Who may be able to join
- Adult (>18y)
- Owing a social security insurance
- Any solid cancer diagnosed by histopathology or cytology
- Patient with blood sampling required as per standard of care
- Informed consent signed
Who cannot join
- Refusal to participate
- No blood sampling required as per standard of care
- Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
- Heterologous blood transfusion in the last 48 hours
- Weight under 20 kg
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
France7 sites, 7 recruiting
- Recruiting
Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est
Bron, 69500
Michaël DURUISSEAUX, Dr, michael.duruisseaux@chu-lyon.fr
- Recruiting
Hôpital Edouard Herriot / Groupement Hospitalier Centre
Lyon, 69003
Mathieu PIOCHE, Pr, 04 72 11 01 49 ext. +33, mathieu.pioche@chu-lyon.fr
- Recruiting
Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord
Lyon, 69004
Lize KIAKOUAMA-MALEKA, Dr, lize.kiakouama-maleka@chu-lyon.fr
- Recruiting
Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Groupement Hospitalier Sud
Pierre-Bénite, 69310
Sebastien COURAUD, MD, PhD, +33 4 478 864 401, sebastien.couraud@chu-lyon.fr
- Recruiting
Hôpital Lyon-Sud / Groupement Hospitalier Sud
Pierre-Bénite, 69495
Olivier GLEHEN, Pr, 04 78 86 23 71 ext. +33, olivier.glehen@chu-lyon.fr
Vahan KEPENEKIAN, Pr, 04 78 86 23 71 ext. +33, vahan.kepenekian@chu-lyon.fr
- Recruiting
Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud
Pierre-Bénite, 69495
Gilles FREYER, Pr, gilles.freyer@chu-lyon.fr
- Recruiting
Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud
Pierre-Bénite, 69495
Stéphane DALLE, Pr, stephane.dalle@chu-lyon.fr
About this study
Official title: MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
- Conditions
- Adult With Solid Cancer
- Being tested
- Blood sampling for biomarker analysis (microRNA, circulating DNA…)
- Keywords
- liquid biopsy, solid cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampling for biomarker analysis (microRNA, circulating DNA…)Biological
From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
| Study group | Role | What they receive |
|---|---|---|
| Adult with solid cancer. No intervention. | Not described Receives: Biological: Blood sampling for biomarker analysis (microRNA, circulating DNA…) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Liquid biopsy analyses
Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.
Measured: Day 0
Standard technics of disease assessment
Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.
Measured: Week 16
Correlation between outcome 1 and outcome 2
Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.
Measured: year 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2021
- Study start5 Dec 2022
- Primary completion1 Dec 2047 (estimated)
- Study completion1 Dec 2047 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult With Solid CancerStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05089747
- Sponsor's protocol ID
- 69HCL21_0918
- Acronym
- CIRCAN MAP
- Status last verified
- Jun 2026
- First submitted
- 11 Oct 2021
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: A decision on sharing individual participant data has not yet been made. Data sharing will depend on sponsor policy, ethical approval, and compliance with applicable regulations.
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
- ClinicalTrials.gov ID
- NCT05089747
- Acronym / sponsor ID
- CIRCAN MAP / 69HCL21_0918
- Conditions
- Adult With Solid Cancer
- Keywords
- liquid biopsy, solid cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 6,000 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 5 Dec 2022 (actual)
- Primary completion
- 1 Dec 2047 (estimated)
- Study completion
- 1 Dec 2047 (estimated)
- First posted
- 22 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult with solid cancer. No intervention. | – | Biological: Blood sampling for biomarker analysis (microRNA, circulating DNA…) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult with solid cancer
Key inclusion criteria (5 listed)
- Adult (>18y)
- Owing a social security insurance
- Any solid cancer diagnosed by histopathology or cytology
- Patient with blood sampling required as per standard of care
- Informed consent signed
Key exclusion criteria (5 listed)
- Refusal to participate
- No blood sampling required as per standard of care
- Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
- Heterologous blood transfusion in the last 48 hours
- Weight under 20 kg
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampling for biomarker analysis (microRNA, circulating DNA…)From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study). | Biological | Adult with solid cancer. No intervention. |
Primary outcome
Liquid biopsy analyses
Time frame: Day 0
Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.
Standard technics of disease assessment
Time frame: Week 16
Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.
Correlation between outcome 1 and outcome 2
Time frame: year 5
Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: Undecided. A decision on sharing individual participant data has not yet been made. Data sharing will depend on sponsor policy, ethical approval, and compliance with applicable regulations.
Related trials for Adult With Solid Cancer
RecruitingPhase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms, Colorectal Neoplasms
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingPhase 1
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Not yet recruitingPhase 1
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
RecruitingPhase 2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adult With Solid Cancer, run by Hospices Civils de Lyon at 7 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sebastian Couraud, MD, PhD (+33 4 478 864 401, sebastien.couraud@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Liquid biopsy analyses (time frame: Day 0). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.